ACRX - AcelRx Pharmaceuticals, Inc.
| Previous Close | 2.1900 |
| Open | 2.2000 |
| Bid | 0.0000 x 800 |
| Ask | 2.2900 x 3200 |
| Day's Range | 2.0200 - 2.2200 |
| 52 Week Range | 1.9900 - 5.0500 |
| Volume | 1,518,199 |
| Avg. Volume | 1,452,965 |
| Market Cap | 172.033M |
| Beta (3Y Monthly) | 2.31 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.7560 |
| Earnings Date | Oct 30, 2017 - Nov 3, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.93 |
- Zacks•14 days ago
Concert Pharma's CTP-692 Positive for Schizophrenia in Phase I
Concert Pharma (CNCE) reports favorable data from the two early-stage studies on its pipeline candidate, CTP-692, currently under evaluation as an adjunctive treatment for schizophrenia. Share rise.
- Thomson Reuters StreetEvents•20 days ago
Edited Transcript of ACRX earnings conference call or presentation 8-May-19 8:30pm GMT
Q1 2019 AcelRx Pharmaceuticals Inc Earnings Call
- PR Newswire•24 days ago
AcelRx announces the closing of a $25 million senior secured debt facility
REDWOOD CITY, Calif., June 3, 2019 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the closing of a $25 million senior secured debt facility with Oxford Finance LLC, a specialty finance firm providing senior debt to life sciences and healthcare services companies worldwide. "We are pleased to announce the closing of this debt financing with Oxford," said Vince Angotti, AcelRx Chief Executive Officer.
- Zacks•last month
AcelRx Pharmaceuticals (ACRX) Upgraded to Buy: Here's Why
AcelRx Pharmaceuticals (ACRX) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Motley Fool•2 months agoAcelRx Pharmaceuticals Inc (ACRX) Q1 2019 Earnings Call Transcript
ACRX earnings call for the period ending March 31, 2019.
- Motley Fool•2 months ago
Here's Why AcelRx Pharmaceuticals Fell as Much as 14% Today
The pharma announced first-quarter 2019 operating results.
- Zacks•2 months ago
AcelRx Pharmaceuticals (ACRX) Reports Q1 Loss, Lags Revenue Estimates
AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 26.09% and -68.64%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•2 months ago
AcelRx Pharmaceuticals: 1Q Earnings Snapshot
The Redwood City, California-based company said it had a loss of 17 cents per share. The results exceeded Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...
- ACCESSWIRE•2 months ago
AcelRx Pharmaceuticals, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / May 8, 2019 / AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 8, 2019 at 4:30 PM ...
- Zacks•2 months ago
What's in the Cards for AcelRx (ACRX) This Earnings Season?
We expect AcelRx (ACRX) to provide update on the launch of its newly approved drug DSUVIA, when it reports first-quarter 2019 results.
- Zacks•2 months ago
Will AcelRx Pharmaceuticals (ACRX) Report Negative Earnings Next Week? What You Should Know
AcelRx Pharmaceuticals (ACRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Motley Fool•2 months ago
3 Stocks Peter Lynch Would Love
They could be big winners for patient investors.
- PR Newswire•2 months ago
AcelRx to announce first quarter 2019 results and provide an update on the company's business on Wednesday, May 8th, 2019
REDWOOD CITY, Calif., April 25, 2019 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (ACRX), a specialty pharmaceutical company, today announced that it will release first quarter financial results after market close on Wednesday, May 8th, 2019. AcelRx management will host a live webcast and conference call at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) on May 8, 2019 to discuss the financial results and provide an update on the company's business. The webcast is accessible by visiting the Investors page of the company's website at www.acelrx.com and clicking on the webcast link on the Investors home page.
- PR Newswire•3 months ago
AcelRx Pharmaceutical's pooled safety results for sufentanil sublingual tablets (DSUVIA) selected for presentation at 44th Annual Regional Anesthesiology & Acute Pain Medicine Meeting
REDWOOD CITY, Calif. , April 11, 2019 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies ...
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of ACRX earnings conference call or presentation 7-Mar-19 9:30pm GMT
Q4 2018 AcelRx Pharmaceuticals Inc Earnings Call
- Zacks•3 months ago
Small Drugmakers Outperforming the Bigshots: 7 Stocks to Buy
Smaller drugmakers are having a relatively better 2019 than their larger counterparts. Here are seven stocks to buy.
- Zacks•3 months ago
AcelRx Pharmaceuticals (ACRX) Upgraded to Buy: What Does It Mean for the Stock?
AcelRx Pharmaceuticals (ACRX) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- PR Newswire•4 months ago
AcelRx Pharmaceuticals to Present at Oppenheimer & Co. Inc. 29th Annual Healthcare Conference
REDWOOD CITY, Calif. , March 11, 2019 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies ...
- Motley Fool•4 months ago
Why AcelRx Pharmaceuticals Stock Is Sinking Today
Investors wanted more good news than they got in the specialty-drug maker's fourth-quarter update.
- Zacks•4 months ago
Here's Why Momentum Investors Will Love AcelRx Pharmaceuticals (ACRX)
Does AcelRx Pharmaceuticals (ACRX) have what it takes to be a top stock pick for momentum investors? Let's find out.
- PR Newswire•4 months ago
AcelRx Pharmaceuticals Announces Commercial Launch of DSUVIA and Reports Fourth Quarter and Full Year 2018 Financial Results
- DSUVIA now available for use in certified medically supervised healthcare settings, with initial shipments to wholesalers completed in the second half of February 2019 - Executed contracts with Group ...
- Motley Fool•4 months ago
3 Top Small-Cap Stocks to Buy Right Now
These three small-cap stocks have outstanding growth potential.
- PR Newswire•4 months ago
AcelRx to announce fourth quarter 2018 results and provide a corporate update on Thursday, March 7th, 2019
REDWOOD CITY, Calif. , Feb. 22, 2019 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release fourth quarter and annual financial ...
- ACCESSWIRE•4 months ago
Biotech Leaders to Watch This Week
HENDERSON, NV / ACCESSWIRE / February 19, 2019 / Biotechnology is coming back strong in 2019 as the iShares Nasdaq Biotechnology Index's 16% surge higher during the first month and a half of this new year ...
